Core Viewpoint - Meili Tianyuan Medical Health (02373) has seen a stock increase of over 6%, currently trading at HKD 28.46, with a transaction volume of HKD 9.5031 million. The company has released a positive profit forecast for 2025, expecting significant revenue and profit growth driven by expansion and strong internal growth momentum [1]. Financial Projections - The company anticipates a revenue of no less than 3 billion yuan for 2025, representing a year-on-year growth of at least 16% [1]. - Adjusted net profit is expected to be no less than 380 million yuan, with a year-on-year increase of at least 40% [1]. - Net profit is projected to be no less than 340 million yuan, reflecting a year-on-year growth of at least 34% [1]. Business Expansion and Market Position - The board attributes the performance improvement to accelerated external expansion and strong internal growth potential [1]. - The integration of Nairui into the Meili Tianyuan brand matrix has allowed the company to penetrate key cities in the Greater Bay Area, significantly enhancing market share [1]. - The synergy effects from the acquisition continue to be released, with Nairui's adjusted net profit margin increasing from 6.5% before the acquisition to 10.4% in the first half of 2025 [1]. Operational Efficiency - The company is continuously upgrading its medical business capabilities, with a steady increase in the proportion of high-margin medical business revenue expected by 2025 [1]. - The ongoing enhancement of the refined operational system is contributing to a gradual increase in the company's net profit margin [1].
美丽田园医疗健康续涨超6% 内生外延驱动成长 去年经调净利同比预增超40%